Image courtesy of Abbott

Abbott Launches Third COVID-19 Test, a Laboratory-Based Antibody Blood Test That Will Ship in the U.S. Starting Tomorrow

Originally posted on Abbott.com

– This adds to Abbott’s previously announced COVID-19 molecular tests: the m2000™ lab-based test and ID NOW™ rapid point-of-care test

– New antibody test will run on Abbott’s ARCHITECT® i1000SR and i2000SR laboratory instruments and will expand to its new Alinity™ i system

– Abbott begins shipping tomorrow and intends to distribute 4 million tests in April, ramping to 20 million in the U.S. per month in June and beyond

Abbott (NYSE: ABT) announced today the launch of its third COVID-19 test, a lab-based serology blood test for the detection of the antibody, IgG, that identifies if a person has had the novel coronavirus (COVID-19). Antibody testing is an important next step to tell if someone has been previously infected. It will provide more understanding of the virus, including how long antibodies stay in the body and if they provide immunity. This type of knowledge could help support the development of treatments and vaccines.

This antibody test adds to Abbott’s existing COVID-19 tests that are already being used, including its m2000 molecular laboratory system and its ID NOW molecular point-of-care device.

“We continue to contribute in a significant and meaningful way by providing new solutions across our diagnostics testing platforms,” said Robert B. Ford, president and chief executive officer, Abbott. “I’m extremely proud of the many Abbott people who are working around the clock to get as many tests as we can to healthcare workers and patients.”

Antibody tests to expand testing and help healthcare workers
While molecular testing detects whether someone has the virus, antibody tests determine if someone was previously infected.

Abbott’s SARS-CoV-2 IgG test identifies the IgG antibody, which is a protein that the body produces in the late stages of infection and may remain for up to months and possibly years after a person has recovered. Abbott’s IgG antibody test will initially be available on its ARCHITECT® i1000SR and i2000SR laboratory instruments*. More than 2,000 of these instruments are in use in U.S. laboratories. These instruments can run up to 100-200 tests per hour.

Abbott is making the test available as part of the U.S. Food and Drug Administration (FDA) notification without an Emergency Use Authorization (EUA) pathway outlined in Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency. Additionally, Abbott plans to file an EUA submission with the FDA and plans to CE Mark to the IVD Directive (98/79/EC) in the European Union.

Abbott is significantly scaling up its manufacturing for antibody testing and is expecting to immediately ship close to 1 million tests this week to U.S. customers, and will ship a total of 4 million tests in total for April. The company is ramping up to 20 million tests in the U.S. in June and beyond as it expands the tests to run on its new Alinity i system. Abbott also will be expanding its laboratory antibody testing to the detection of the antibody, IgM, in the near future.

 

Latest News

5 Biggest News Stories of the Week: October 6

As the saying goes, the news never stops — but there’s a lot of it out there, and all of it doesn’t always pertain to our readers. In this weekly news roundup, we’ll cover the top news stories that matter most to our diversity focused audience. 1. The Dollar Divide…

WOCA 2022 Research: How to Improve Representation of Women of Color in the Workplace 

Capital One and DiversityInc shared the results of their collaborative research report on women of color in the workplace at the 2022 annual Women of Color and Their Allies event held in Louisville on Sept. 21 in conjunction with Humana. Dr. Chris Parker, Head of Research & Data, DiversityInc, confirmed…

WOCA 2022: Executive Leaders Share Stories of Allyship for Women of Color

One of the best indicators of an organization’s success around diversity, equity and inclusion (DEI) is leadership accountability for DEI. At our 2022 Women of Color and Their Allies event, DiversityInc’s Head of Strategic Partnerships, Anita Ricketts, was joined on stage by leaders who are holding themselves and their contemporaries…

The Dollar Divide

Too Poor to Die: The Rising Cost of Funerals 

Death is expensive.  For more than two decades, I have extensively written and reported about money-related content and even I was surprised at the cost of my mother’s funeral.  The median cost of a funeral with a viewing and burial is approximately $7,848. That doesn’t include the cost of the…